FOLFIRINOX Improves PFS Compared with Gemcitabine in Patients with Locally Advanced Pancreatic Carcinoma By Ogkologos - May 26, 2025 274 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PRODIGE 29-UCGI 26 (NEOPAN) study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR Removing senescent immune cells could be the key to preventing some... June 1, 2023 Coping With Cancer Recurrence: My Perspective As Both a Patient and... January 24, 2023 Melanoma Combination Studies with a Novel Anti-LAG3 Antibody Relatlimab June 11, 2021 Fisioterapeutas en oncología October 12, 2021 Load more HOT NEWS How to Stay Connected When Your Partner Has Cancer FDA Approves Polatuzumab Vedotin-piiq for Previously Untreated Diffuse Large B-Cell Lymphoma,... Potential of Molecular Profiling to Refine Surgical and Radiotherapy Decision-Making in... “My Heart Will Always Hurt”: How I Honor My Childhood Best...
